Autopsy report · NCT00706992

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

“\<11 subjects were enrolled to each Arm”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 5 months before it stopped.
• 50 participants enrolled.
• Results were posted on the registry 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Melanoma

Interventions

ALVAC-MART-1 vaccine; MART-1:26-35(27L) peptide vaccine; Aldesleukin; autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes; incomplete Freund's adjuvant

Participants

50

Sites

1

Countries

United States

Trials that died the same way

• Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque
  “It was felt that a sufficient number of subjects were enrolled.” (61% match in meaning)
• mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment
  “Due to difficulties in recruitment and completion rates, the study was considered to be not feasible. After 4 years, only 12 participants were randomized. Of the 8 mSIM arm participants, only 2 completed the study.” (57% match in meaning)
• A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
  “Three subjects were enrolled and all three subjects withdrew.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.